Veranova provides an extensive portfolio of generic APIs. Our products cover a wide range of therapeutic classes, such as anti-cancer, anti-addiction, psychiatric disorders, and pain management.

Our API offering is supported by our network of GMP-compliant commercial manufacturing facilities in Europe and North America, to meet your global product requirements.

Download API and Controlled Substance Product Guide
 

API products

Filter by:

Apomorphine HCl

CAS number: 41372-20-7
See more

Atropine Sulfate

CAS number: 5908-99-6
See more

Auranofin

CAS number: 34031-32-8
See more

Carboplatin

CAS number: 41575-94-4
See more

Carmustine

CAS number: 154-93-8
See more

Cisplatin

CAS number: 15663-27-1
See more

Decitabine

CAS number: 2353-33-5
See more

Dofetilide

CAS number: 115256-11-6
See more

Edrophonium Chloride

CAS number: 116-38-1
See more

Isoproterenol HCl

CAS number: 51-30-9
See more

Lurasidone HCl

CAS number: 367514-88-3
See more

Miglustat

CAS number: 72599-27-0
See more

Naloxone HCl

CAS number: 51481-60-8
See more

Nintedanib

CAS number: 656247-18-6
See more

Pirfenidone

CAS number: 53179-13-8
See more

Controlled substances

Learn more

Featured insights from our experts

Read more

Nanomilling: A Key Technology for Enhancing Drug Delivery

Nanomilling is a particle-size reduction technique that can enhance the dissolution rate of poorly soluble active pharmaceutical ingredients (APIs) and therefore their bioavailability. This technology can also open opportunities for novel formulations.

Analytical Challenges for Antibody-Drug Conjugate (ADC) Manufacturing

Read our latest eBook that explores the critical challenges shaping ADC development today, from analytical strategy and impurity control to linker technology innovations and evolving regulatory standards. It also examines the collaborative expertise needed to bring these transformative therapies to patients.

Review of the FDA Draft Guidance on AI in Drug Development

In this article, Kishore Vatsavai, Principal Scientist, outlines the key takeaways from the FDA’s draft guidance, offers real-world examples of how AI is being applied in drug development today, and shares strategies to help mitigate bias and model drift, along with practical resources for those interested in learning more.

Veranova is your next great decision

Discover new ways to advance your science with Veranova.

Contact us